Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.
Identifieur interne : 001833 ( PubMed/Curation ); précédent : 001832; suivant : 001834Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.
Auteurs : Shunsuke Kohyama [Japon] ; Satoshi Ohno ; Tatsuya Suda ; Maiko Taneichi ; Shoichi Yokoyama ; Masahito Mori ; Akiharu Kobayashi ; Hidenori Hayashi ; Tetsuya Uchida ; Masanori MatsuiSource :
- Antiviral research [ 1872-9096 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Données de séquences moléculaires, Déterminants antigéniques des lymphocytes T (), Humains, Immunisation, Lignée cellulaire, Liposomes (), Liposomes (administration et posologie), Liposomes (immunologie), Lymphocytes T cytotoxiques (), Lymphocytes T cytotoxiques (immunologie), Peptides (), Peptides (administration et posologie), Peptides (immunologie), Protéines virales non structurales (), Protéines virales non structurales (immunologie), RNA replicase (), RNA replicase (immunologie), Souris, Souris transgéniques, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Séquence d'acides aminés, Séquence nucléotidique, Vaccins antiviraux, Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Liposomes, Peptides.
- immunologie : Liposomes, Lymphocytes T cytotoxiques, Peptides, Protéines virales non structurales, RNA replicase, Syndrome respiratoire aigu sévère, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Données de séquences moléculaires, Déterminants antigéniques des lymphocytes T, Humains, Immunisation, Lignée cellulaire, Liposomes, Lymphocytes T cytotoxiques, Peptides, Protéines virales non structurales, RNA replicase, Souris, Souris transgéniques, Syndrome respiratoire aigu sévère, Séquence d'acides aminés, Séquence nucléotidique, Vaccins antiviraux.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Base Sequence, Cell Line, Epitopes, T-Lymphocyte (chemistry), Humans, Immunization, Liposomes (administration & dosage), Liposomes (chemistry), Liposomes (immunology), Mice, Mice, Transgenic, Molecular Sequence Data, Peptides (administration & dosage), Peptides (chemistry), Peptides (immunology), RNA Replicase (chemistry), RNA Replicase (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), T-Lymphocytes, Cytotoxic (chemistry), T-Lymphocytes, Cytotoxic (immunology), Viral Nonstructural Proteins (chemistry), Viral Nonstructural Proteins (immunology), Viral Vaccines.
- MESH :
- chemical , administration & dosage : Liposomes, Peptides.
- chemical , chemistry : Epitopes, T-Lymphocyte, Liposomes, Peptides, RNA Replicase, Viral Nonstructural Proteins.
- chemical , immunology : Liposomes, Peptides, RNA Replicase, Viral Nonstructural Proteins.
- chemistry : T-Lymphocytes, Cytotoxic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes, Cytotoxic.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Base Sequence, Cell Line, Humans, Immunization, Mice, Mice, Transgenic, Molecular Sequence Data, Viral Vaccines.
Abstract
Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A*0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (pp1a) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-gamma)-producing CD8(+) T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-gamma-producing CD8(+) T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A*0201 positive cell line expressing naturally processed, pp1a-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from pp1a might offer an efficient CTL-based vaccine against SARS.
DOI: 10.1016/j.antiviral.2009.09.004
PubMed: 19748524
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001833
Links to Exploration step
pubmed:19748524Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.</title><author><name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama</wicri:regionArea></affiliation></author><author><name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name></author><author><name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name></author><author><name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name></author><author><name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name></author><author><name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name></author><author><name sortKey="Kobayashi, Akiharu" sort="Kobayashi, Akiharu" uniqKey="Kobayashi A" first="Akiharu" last="Kobayashi">Akiharu Kobayashi</name></author><author><name sortKey="Hayashi, Hidenori" sort="Hayashi, Hidenori" uniqKey="Hayashi H" first="Hidenori" last="Hayashi">Hidenori Hayashi</name></author><author><name sortKey="Uchida, Tetsuya" sort="Uchida, Tetsuya" uniqKey="Uchida T" first="Tetsuya" last="Uchida">Tetsuya Uchida</name></author><author><name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19748524</idno><idno type="pmid">19748524</idno><idno type="doi">10.1016/j.antiviral.2009.09.004</idno><idno type="wicri:Area/PubMed/Corpus">001833</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001833</idno><idno type="wicri:Area/PubMed/Curation">001833</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001833</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.</title><author><name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama</wicri:regionArea></affiliation></author><author><name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name></author><author><name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name></author><author><name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name></author><author><name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name></author><author><name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name></author><author><name sortKey="Kobayashi, Akiharu" sort="Kobayashi, Akiharu" uniqKey="Kobayashi A" first="Akiharu" last="Kobayashi">Akiharu Kobayashi</name></author><author><name sortKey="Hayashi, Hidenori" sort="Hayashi, Hidenori" uniqKey="Hayashi H" first="Hidenori" last="Hayashi">Hidenori Hayashi</name></author><author><name sortKey="Uchida, Tetsuya" sort="Uchida, Tetsuya" uniqKey="Uchida T" first="Tetsuya" last="Uchida">Tetsuya Uchida</name></author><author><name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Base Sequence</term><term>Cell Line</term><term>Epitopes, T-Lymphocyte (chemistry)</term><term>Humans</term><term>Immunization</term><term>Liposomes (administration & dosage)</term><term>Liposomes (chemistry)</term><term>Liposomes (immunology)</term><term>Mice</term><term>Mice, Transgenic</term><term>Molecular Sequence Data</term><term>Peptides (administration & dosage)</term><term>Peptides (chemistry)</term><term>Peptides (immunology)</term><term>RNA Replicase (chemistry)</term><term>RNA Replicase (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>T-Lymphocytes, Cytotoxic (chemistry)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Viral Nonstructural Proteins (chemistry)</term><term>Viral Nonstructural Proteins (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Données de séquences moléculaires</term><term>Déterminants antigéniques des lymphocytes T ()</term><term>Humains</term><term>Immunisation</term><term>Lignée cellulaire</term><term>Liposomes ()</term><term>Liposomes (administration et posologie)</term><term>Liposomes (immunologie)</term><term>Lymphocytes T cytotoxiques ()</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Peptides ()</term><term>Peptides (administration et posologie)</term><term>Peptides (immunologie)</term><term>Protéines virales non structurales ()</term><term>Protéines virales non structurales (immunologie)</term><term>RNA replicase ()</term><term>RNA replicase (immunologie)</term><term>Souris</term><term>Souris transgéniques</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Séquence d'acides aminés</term><term>Séquence nucléotidique</term><term>Vaccins antiviraux</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Liposomes</term><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>Liposomes</term><term>Peptides</term><term>RNA Replicase</term><term>Viral Nonstructural Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Liposomes</term><term>Peptides</term><term>RNA Replicase</term><term>Viral Nonstructural Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Liposomes</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Liposomes</term><term>Lymphocytes T cytotoxiques</term><term>Peptides</term><term>Protéines virales non structurales</term><term>RNA replicase</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Base Sequence</term><term>Cell Line</term><term>Humans</term><term>Immunization</term><term>Mice</term><term>Mice, Transgenic</term><term>Molecular Sequence Data</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Données de séquences moléculaires</term><term>Déterminants antigéniques des lymphocytes T</term><term>Humains</term><term>Immunisation</term><term>Lignée cellulaire</term><term>Liposomes</term><term>Lymphocytes T cytotoxiques</term><term>Peptides</term><term>Protéines virales non structurales</term><term>RNA replicase</term><term>Souris</term><term>Souris transgéniques</term><term>Syndrome respiratoire aigu sévère</term><term>Séquence d'acides aminés</term><term>Séquence nucléotidique</term><term>Vaccins antiviraux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A*0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (pp1a) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-gamma)-producing CD8(+) T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-gamma-producing CD8(+) T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A*0201 positive cell line expressing naturally processed, pp1a-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from pp1a might offer an efficient CTL-based vaccine against SARS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19748524</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.</ArticleTitle><Pagination><MedlinePgn>168-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2009.09.004</ELocationID><Abstract><AbstractText>Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A*0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (pp1a) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-gamma)-producing CD8(+) T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-gamma-producing CD8(+) T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A*0201 positive cell line expressing naturally processed, pp1a-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from pp1a might offer an efficient CTL-based vaccine against SARS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohyama</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Suda</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Taneichi</LastName><ForeName>Maiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Shoichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Masahito</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Akiharu</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="C521592">Nsp1 protein, SARS coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="Y">Liposomes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="Y">Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="Y">RNA Replicase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="Y">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748524</ArticleId><ArticleId IdType="pii">S0166-3542(09)00457-4</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC7114085</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>QJM. 2003 Nov;96(11):845-52</Citation><ArticleIdList><ArticleId IdType="pubmed">14566040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2007 Jun 21;25(26):4914-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17531358</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2009 Jun 12;27(29):3912-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19490987</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Immunol. 1981 Dec;3(4):277-99</Citation><ArticleIdList><ArticleId IdType="pubmed">7035415</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1991 May 15;146(10):3508-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2026879</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Oct;79(20):12798-806</Citation><ArticleIdList><ArticleId IdType="pubmed">16188982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2005 Jul 1;175(1):591-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15972696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2005 Oct 1;175(7):4618-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16177107</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Med Genet. 2003 Sep 12;4:9</Citation><ArticleIdList><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Invest. 2007 Nov;117(11):3563-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17975674</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2004 Apr 5;199(7):905-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15067030</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2004 Nov;34(11):3102-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15368273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 1995 Jun;145:5-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7590830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 1985;21(3):235-46</Citation><ArticleIdList><ArticleId IdType="pubmed">3872841</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):201-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10602880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2324-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16887993</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chin Med J (Engl). 2003 Jun;116(6):827-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12877788</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16630549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Aug 1;190(3):515-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15243926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1994 Jan 1;152(1):163-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8254189</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2006 Summer;19(3):458-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16987064</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cancer Res. 2003 Jun 15;63(12):3281-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12810660</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respir Res. 2005 Jan 20;6:8</Citation><ArticleIdList><ArticleId IdType="pubmed">15661082</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2003 Sep 15;198(6):889-901</Citation><ArticleIdList><ArticleId IdType="pubmed">12975455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mucosal Immunol. 2009 Mar;2(2):129-143</Citation><ArticleIdList><ArticleId IdType="pubmed">19129756</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 1997 Jun 16;185(12):2043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9182675</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2008 Jan 1;180(1):426-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18097044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2002 Aug;106(4):526-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12153516</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Sep;78(17):9093-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15308705</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):7069-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15194783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001833 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001833 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19748524
|texte= Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19748524" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |